Last reviewed · How we verify
Clofenamidum — Competitive Intelligence Brief
phase 2
clofenamide
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Clofenamidum (CLOFENAMIDE). Clofenamidum is believed to work by modulating the activity of certain enzymes or receptors, although the specific details of its mechanism are not well understood.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clofenamidum TARGET | CLOFENAMIDE | phase 2 | clofenamide |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (clofenamide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clofenamidum CI watch — RSS
- Clofenamidum CI watch — Atom
- Clofenamidum CI watch — JSON
- Clofenamidum alone — RSS
- Whole clofenamide class — RSS
Cite this brief
Drug Landscape (2026). Clofenamidum — Competitive Intelligence Brief. https://druglandscape.com/ci/clofenamide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing